Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • BioNTech

    - PMLiVE

    UK and US agree on landmark pharma pricing tariff deal

    US tariffs on UK-produced pharmaceuticals will remain at zero for three years

    - PMLiVE

    ViiV Healthcare receives NICE recommendation for HIV prevention therapy

    The treatment is the first and only long-acting HIV prevention option available on the NHS in England and Wales

    - PMLiVE

    New National Commission launched to strengthen AI regulation

    The Commission will unite healthcare leaders, regulators and technology experts to shape future AI governance

    - PMLiVE

    NHS programme to give head and neck cancer patients fast-track access to mRNA vaccine

    More than 11,000 people are diagnosed with head and neck cancers every year in England

    Navigating NHS Market Access: Policy Change and Opportunity in England With Sarah Everest Ford

    Navigating NHS Market Access: Policy Change and Opportunity in England

    With the changes at NHS England and the publishing of the 10-Year Plan, there is a lot of talk of change in the NHS in England. But what do these...

    Petauri Evidence

    - PMLiVE

    Digital Transformation in the NHS’s 10-Year Plan: Techno-Optimism and the Limits of Efficiency

    Here, Evelyne Priestman (Senior Consultant – HEOR) and Mary Baker (Senior Medical Writer) at Petauri Evidence explore the National Health Service (NHS) in England’s newly unveiled 10-year plan through the...

    Petauri Evidence

    - PMLiVE

    NICE recommends BeOne’s Brukinsa to treat mantle cell lymphoma on NHS

    Approximately 600 people are affected by the form of non-Hodgkin lymphoma every year in the UK

    - PMLiVE

    UK government publishes 10 Year Health Plan for England to ‘reinvent’ NHS

    The plan’s three overarching themes are hospital to community, analogue to digital and sickness to prevention

    - PMLiVE

    Merck’s perioperative Keytruda regimen approved by FDA for head and neck cancer

    More than 72,680 new cases of the disease are expected to be diagnosed in the US this year

    - PMLiVE

    BioNTech expands mRNA capabilities with $1.25bn CureVac acquisition

    The deal will support the advancement of BioNTech’s mRNA-based cancer immunotherapies

    - PMLiVE

    BMS and BioNTech partner on solid tumour candidate in deal worth over $11bn

    BioNTech’s BNT327 is being evaluated in multiple clinical trials, including phase 3 studies in first-line lung cancer

    - PMLiVE

    BioNTech announces £1bn UK investment to boost regional R&D presence

    The UK government has also agreed to award the company a grant of up to £129m

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links